GlassScriptPhysician profile
Lynn Susan Osher
NPI 1407934920
$2,905.28
in general payments reported to CMS, 2019-2025
27 companies · $647 in 2025
The $647 reported for 2025 was more than what 95% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $268 · 2021: $322 · 2022: $165 · 2023: $556 · 2024: $643 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,846.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $480.69 | 2019-2024 | Auvi-Q |
| Sanofi Pasteur INC. | $289.77 | 2019-2025 | |
| Pfizer INC. | $279.13 | 2019-2024 | |
| Corium, LLC | $263.88 | 2021-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $212.65 | 2019-2025 | Gardasil 9, Vaxneuvance, Enflonsia |
| Cranial Technologies, INC | $196.30 | 2019-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $140.65 | 2020-2021 | |
| Novo Nordisk INC | $133.19 | 2024 | Wegovy, Saxenda |
| Glaxosmithkline, LLC. | $116.74 | 2019-2023 | Bexsero |
| Regeneron Healthcare Solutions, INC. | $104.17 | 2024 | Dupixent |
| Verrica Pharmaceuticals INC. | $99.48 | 2023-2025 | Ycanth |
| Biofire Diagnostics, LLC | $73.67 | 2019 | |
| Sanofi-Aventis U.S. LLC | $71.54 | 2024-2025 | |
| Phadia US INC. | $61.84 | 2023-2025 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $53.22 | 2021-2023 | Flumist Quadrivalent |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $50.92 | 2025 | Neffy |
| Horizon Therapeutics Plc | $44.70 | 2019-2020 | |
| Seqirus USA INC | $38.39 | 2025 | Flucelvax, Fluad |
| Abbott Laboratories | $27.44 | 2025 | Id Now Instrument |
| Cognoa, INC. | $26.10 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $25.38 | 2025 | Neffy |
| Noven Therapeutics, LLC | $24.48 | 2024 | Xelstrym |
| Mayne Pharma Commercial LLC | $21.40 | 2023 | |
| Supernus Pharmaceuticals, INC. | $20.26 | 2025 | Qelbree |
| Genzyme Corporation | $19.55 | 2022 | |
| Advanced Respiratory, INC | $17.04 | 2019 | |
| Shire North American Group INC | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Osher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.